[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,91,0,25,[9,56,85,113,147,196,217,245,273,295,316,337,357,381,408,441,464,498,515,537,564,587,612,646,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":41,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100652162","phase-1-a-study-of-sonrotoclax-bgb-11417-in-children-with-relapsed-or-refractory-acute-myeloid-leukemia-and-b-cell-acute-lymphoblastic-leukemia-100652162",false,"NCT07770698","A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia","A Phase 1\u002F2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sonrotoclax (BGB-11417) in Combination With Other Agents in Pediatric Patients Aged 6 Months to 17 Years, With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia","Key Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n1. Have a performance status of Lansky ≥50 for participants ≤16 years of age or Karnofsky ≥50 for participants \\>16 years of age.\n2. Have adequate renal function, defined as an estimated or measured glomerular filtration rate (GFR) ≥60 mL\u002Fmin.\n3. Have adequate hepatic function, defined as:\n\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C2.5 × the institutional upper limit of normal (ULN)\n   * Total bilirubin ≤1.5 × the institutional ULN.\n4. Have minimum cardiac function as defined in the study protocol.\n\nAcute Myeloid Leukemia (AML)-Specific Inclusion Criteria\n\n1. Have a histologically confirmed diagnosis of acute myeloid leukemia (AML) that is relapsed or refractory (R\u002FR) after ≥2 prior lines of systemic therapy.\n2. Have ≥5% blasts in a bone marrow aspirate or biopsy sample, as assessed by morphology. Participants with extramedullary, non-central nervous system (CNS) disease are eligible.\n\nB-Cell Precursor Acute Lymphoblastic Leukemia (ALL)-Specific Inclusion Criteria\n\n1. Have a histologically confirmed diagnosis of B-cell precursor acute lymphoblastic leukemia (ALL) that is R\u002FR after ≥2 prior lines of systemic therapy, including at least 1 line of blinatumomab-based therapy.\n2. Have ≥5% blasts in a bone marrow aspirate or biopsy sample, as assessed by morphology.\n3. Have leukemic blasts expressing cluster of differentiation 22 (CD22) on the cell surface, as assessed by flow cytometry of a bone marrow aspirate.\n\nKey Exclusion Criteria\n\nParticipants will be excluded from participation if any of the following apply:\n\n1. Have central nervous system (CNS) 2 or CNS 3 disease at screening.\n2. Have toxicity from prior anticancer therapy that has not recovered to ≤Grade 1, as defined by the applicable toxicity grading criteria.\n3. Have a history of prior allogeneic stem cell transplantation \\\u003C90 days from enrollment or if if ≥ 90 days from enrollment, with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent.\n\nAML-Specific Exclusion Criteria\n\n1. Have a diagnosis of acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML).\n2. Have AML with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), as determined by local assessment.\n\nALL-Specific Exclusion Criteria\n\n1. Have Philadelphia chromosome-positive (Ph+) ALL with a breakpoint cluster region::Abelson murine leukemia viral oncogene homolog 1 (BCR::ABL1) fusion.\n2. Have received prior therapy with a B-cell lymphoma 2 (BCL-2) inhibitor.\n\nNote: Other eligibility criteria may apply.","ALL","6 Months","17 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment or has not responded to treatment. The study will also learn how the body processes sonrotoclax when it is given with other medicines. The main questions it aims to answer are:\n\n* Is sonrotoclax safe and well tolerated when given with other anti-cancer medicines?\n* How does the body absorb, process, and remove sonrotoclax?\n* Does treatment with sonrotoclax, in combination with other medicines, help reduce or eliminate leukemia?\n\nResearchers will give sonrotoclax together with other anti-cancer medicines to participants with relapsed or refractory AML or ALL. Participants will:\n\n* Take sonrotoclax in combination with other anti-cancer medicines\n* Have regular clinic visits for physical exams, blood tests, heart monitoring, and other safety assessments.\n* Provide blood samples to measure how the body processes sonrotoclax.\n* Have tests to evaluate how their leukemia responds to treatment.\n* Continue treatment as long as it is helping and side effects remain manageable, according to the study plan.",[29,30,31,32,33,34,35,36,37,38,39,40],"Relapsed Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","B-cell Acute Lymphoblastic Leukemia","Pediatric Cancer","Pediatric ALL, Relapsed","Pediatric ALL","Pediatric ALL, B Cell","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Pediatric AML","R\u002FR AML","R\u002FR B-cell ALL",[40,39,38,37,36,35,34,33,32,29,30,42,43],"Sonrotoclax","Pediatric","NOT_YET_RECRUITING","2026-08-17",{"date":47,"type":48},"2026-08-18","ACTUAL",{"date":50,"type":22},"2026-10",{"date":52,"type":22},"2031-09",{"name":54,"class":55},"BeOne Medicines","INDUSTRY",{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100641380","music-therapy-for-oral-mucositis-pain-in-pediatric-patients-100641380","NCT07653360","Music Therapy for Oral Mucositis Pain in Pediatric Patients","Effect of Music Therapy on Oral Mucositis Pain in Pediatric Patients","Inclusion Criteria:\n\nPhase 1\n\n* Child ages 6-18 years old\n* Child has received music therapy and experienced oral mucositis\n* Parent\u002Fguardian 18 years and older\n* Able to communicate in English\n\nExclusion Criteria:\n\nPhase 1\n\n* Diagnosis of a developmental disorder that would prevent engagement in the active music-making or passive music-listening intervention or completion of study measures.\n* Significant pre-existing hearing loss or impairment that would interfere with participation in the interventions.",true,"6 Years","64 Years",{"count":67,"type":22},50,[69],"NA","This mixed-methods pilot study will examine the effect of music therapy on oral mucositis pain in pediatric oncology patients. Oral mucositis, characterized by painful ulcerative lesions in the mouth, is a common side effect of high-dose chemotherapy and hematopoietic stem cell or bone marrow transplantation. Despite its high prevalence and impact on quality of life, effective pain management strategies for pediatric oral mucositis remain limited and often rely heavily on medications that may cause significant side effects or provide insufficient relief. Music therapy may offer a promising non-pharmacologic adjunct for reducing pain, yet no studies to date have specifically evaluated its use for oral mucositis pain in pediatric patients.",[72,32,73],"Oral Mucosa Discomfort","Mucositis Oral",[75],"Music Therapy",{"date":47,"type":48},{"date":78,"type":22},"2026-09-01",{"date":80,"type":22},"2027-07-31",{"name":82,"class":83},"University of California, San Francisco","OTHER",1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":4,"leadSponsor":110,"locationsCount":84},"100054261","psychological-benefits-of-a-normalized-camping-experience-for-children-with-cancer-100054261","NCT00001186","Psychological Benefits of a Normalized Camping Experience for Children With Cancer","* INCLUSION CRITERIA:\n* Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.\n\nOR\n\nYoung adults with cancer (YACers) 18-25 years of age who are acting as counselors at Camp Fantastic.\n\n* Children\u002Fyoung adults will be selected for camp after careful screening by a multidisciplinary committee consisting of medical and program directors. While the state of the child s health will certainly be considered there will be no exclusions for:\n* Patients who are receiving intramuscular, intrathecal, oral or intravenous medications or blood products.\n* Patients who have had amputations or have other physical defects.\n* Patients who become febrile and neutropenic at the onset or during the week of camp will stay at camp on antibiotic therapy providing their condition remains stable.\n* At the discretion of the multidisciplinary committee consisting of medical and program directors, special exceptions may be made for patients with extenuating circumstances.\n* All children will be officially enrolled and will have an NIH Clinical Center Patient Care Number. The enrollment of a child, signing of protocol consent, and completion of admission paperwork is done in person but under extenuating circumstances it may be done over the phone after the paperwork has been mailed to the parent\u002Fguardian. Extenuating circumstances would include a last minute application to camp after the trip for camp screenings in Norfolk or Richmond has been completed.\n\nEXCLUSION CRITERIA:\n\n-Children with a medical diagnosis other than cancer or their related disorders.","7 Years","25 Years",{"count":94,"type":22},5000,"OBSERVATIONAL","Background:\n\n* Cancer has an enormous impact on the psychological and social well-being of the family unit. The life-threatening connotations of cancer single out the ill child from his peer\u002Ffamily group as one who is different, and often unable to maintain a normal lifestyle. Physical sequelae of cancer and its treatment accentuate the differences between these children and their normal peers\u002Fsiblings.\n* It is important that children with cancer be prepared to function outside of protected situations and begin to develop skills of separation and independence. For healthy children, some of these latter skills are acquired by a camping experience. Such an experience for the patient with cancer is frequently precluded by their dependence on medical facilities and the physical limitations of their activities.\n* The goal of this study will be to assess the short and long term benefits of the \"normalized\" camping experience, provided in conjunction with Special Love, Inc., on the patients and staff. In particular, we will seek to determine whether such a comprehensive experience is capable of influencing the attitudes and life experiences of patients and staff in a positive manner.\n\nObjectives:\n\n-To evaluate the impact of an enriched normalized camping experience on the quality of life of the pediatric cancer patient. In particular, attempts will be made to measure the manner in which this experience influences the child's sense of well-being and self-esteem as well as his or her relationship with parents, family, and peers.\n\nEligibility:\n\n* Children 7-17 years of age who are currently being treated for cancer or are up to 3 years post therapy OR Young adults with cancer (YACers) 18-25 years of age who are acting as counselors at Camp Fantastic\n* All children\u002Fyoung adults will be selected for camp after careful screening by a multidisciplinary committee consisting of medical and program directors.\n* At the discretion of the multidisciplinary committee consisting of medical and program directors, special exceptions may be made for children with extenuating circumstances.\n\nDesign:\n\n* Assessment of benefit may include interviews with children and families before, during and following camp. Observational data on the child's performance at camp will be noted.\n* Medical and nursing personnel will consist of staff from the Pediatric Branch at the NCI, other units within the NIH, and participating institutions.\n* Special Love members, the Program Director at the 4-H Center camp (site of the camp) and Pediatric Branch staff at the NCI will coordinate the camp program, taking into account the medical needs of each camper.\n* Every attempt will be made to provide a full agenda of age appropriate activities for the patients.\n* The length of the camping experience for children with cancer will be for 7 days beginning on a Sunday and extending through the following Saturday morning. Patients will be transported to the camp from the NIH Clinical Center and the Virginia hospitals by bus.",[32],[99,100,101,102,103,104],"Psychosocial","Self Esteem","Oncology","Well-Being","Pediatrics","Natural History","RECRUITING","2026-08-15",{"date":47,"type":48},{"date":109,"type":48},"1983-02-15",{"name":111,"class":112},"National Cancer Institute (NCI)","NIH",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":120,"maxAge":19,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100652399","phase-1-study-of-zanzalintinib-in-children-and-adolescents-with-relapsed-or-refractory-solid-tumors-100652399","NCT07773454","Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors","A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors","Key Inclusion Criteria:\n\n* Participants must be \\\u003C 17 years old.\n* Participants must have a minimum body weight of ≥ 10 kilograms (kg) at enrollment.\n* Performance status of ≥ 50% as measured by Lansky for participants \\\u003C 16 years of age or Karnofsky for participants ≥ 16 years of age.\n* Have a relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma).\n\nKey Exclusion Criteria:\n\n* For participants with CNS primary tumors, evidence of intracranial or intratumoral hemorrhage are excluded.\n* Diagnosis of lymphoma.\n* Lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","12 Months",{"count":122,"type":22},18,[25],"The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and\u002For recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.",[126,32],"Cancer",[128,129,130,131,132,133,134,135,136,137],"Solid tumors","Brain tumors","Nervous system tumors","Relapsed","Refractory","Sarcoma and\u002For osteosarcoma","Central nervous system (CNS)","Neuroendocrine tumors","Progressed","Brain","2026-08-12",{"date":140,"type":48},"2026-08-19",{"date":142,"type":22},"2026-09-30",{"date":144,"type":22},"2028-07-31",{"name":146,"class":55},"Exelixis",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":172,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100645242","phase-2-illuminate-a-clinical-study-evaluating-car-t-immune-cell-therapy-bcb-276-for-patients-with-diffuse-intrinsic-pontine-glioma-dipg-100645242","NCT07680439","Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma","Inclusion Criteria:\n\n* Participants must be aged 1 and ≤ 26 years and weigh ≥10kg.\n* Diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) based on imaging, with or without biopsy confirmation consistent with high-grade glioma or diffuse midline glioma\n* Able to tolerate leukapheresis and other study procedures in the opinion of the Investigator.\n* Central Nervous System (CNS) reservoir catheter present prior to first dose of study drug.\n* Participant must have completed standard radiation therapy within 6 weeks of enrollment for participation.\n* Performance Status of ≥ 60; mild to moderate restriction or better. Lansky (under 16 years of age) or Karnofsky (16 years of age or older).\n* Adequate organ function and overall clinical status to participate, including stable or improving neurologic symptoms.\n* Participants of childbearing\u002Ffathering potential must agree to use highly effective contraception from the time of enrollment through 12 months following the last T cell infusion.\n* Participants with ventriculoperitoneal (VP) shunts need to have a programable system and be able to tolerate temporary adjustment of the shunt required for study treatment.\n* Participant must meet all other health and safety criteria defined in the study protocol.\n* Participant and\u002For authorized legal representative willing to provide consent\u002Fassent for study participation, including participation in the 15-year long term follow up period.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Previous tumor-directed therapy or treatment-directed clinical study other than standard radiation with or without temozolamide.\n* Evidence of metastatic disease.\n* Requirement of high or increasing doses of corticosteroids prior to participation.\n* Severe swallowing difficulties or other significant clinical conditions that may interfere with participation.\n* Presence of an active malignancy other than DIPG.\n* Active or uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection based on protocol-required laboratory testing.\n* Pregnant or breastfeeding.\n* Presence of any condition that, in the Investigator's opinion, would prohibit the participant from undergoing treatment under this protocol.","1 Year","26 Years",{"count":157,"type":22},75,[26],"This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG.\n\nTo participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study.\n\nBCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.",[161,162,163,164,165,32,166,167,168,169,170,171],"Diffuse Intrinsic Pontine Glioma","DIPG","Brain Tumor","CNS Tumor","Central Nervous System Tumor","Adult Cancer Patients","CNS Tumor, Childhood","CNS Tumor, Adult","Brainstem Glioma","Diffuse Midline Glioma","DMG",[173,174,175,176,177,178,179,180,181,43,182,183,184,185],"BCB-276","B7-H3-specific Chimeric Antigen Receptor [CAR] T cell therapy","B7-H3","B7-H3 CAR T","B7-H3 CAR T Cells","Chimeric antigen receptor T cells","CAR T Cell","Immunotherapy","Cell Therapy","Children","Adolescent","Young Adult","Adult","2026-08-01",{"date":188,"type":48},"2026-08-04",{"date":190,"type":22},"2026-08",{"date":192,"type":22},"2030-07",{"name":194,"class":55},"BrainChild Bio, Inc",6,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100591352","the-comparative-effectiveness-evaluation-of-the-impact-of-digital-education-100591352","NCT06979310","The Comparative Effectiveness Evaluation of the Impact of Digital Education","The Comparative Effectiveness Evaluation of the Impact of Digital Education Via Text Message Versus Multimedia Modules on Caregiver Knowledge","Inclusion Criteria:\n\n* a known pediatric cancer diagnosis\n* Adult caregivers of children with cancer (\\\u003C18yo) at time of new patient registration\n* Ability to understand and speak Swahili\n* If illiterate, availability of a household member who can read Swahili\n* Be able to access the messages\n\nExclusion Criteria:\n\n* any potential participant who is unable to access messages will also be excluded.\n* Non cancer pediatric diagnosis","18 Years",{"count":205,"type":22},400,[69],"This study is being conducted to determine how best to educate caregivers about cancer and its treatment. When caregivers are well-informed, they are more confident in supporting their child through treatment, which can improve treatment adherence.",[32],"2026-07-28",{"date":211,"type":48},"2026-07-29",{"date":106,"type":22},{"date":214,"type":22},"2028-08-31",{"name":216,"class":83},"Duke University",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":92,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100551280","phase-2-selpercatinib-pre-rai-in-patients-with-ret-fusion-thyroid-cancer-raise-100551280","NCT06458036","Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)","Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions","RAISE","Inclusion Criteria:\n\n1. Age 2-25 years, inclusive\n2. Histologic diagnosis of a differentiated thyroid cancer, status post thyroidectomy and adequate local therapy (e.g., lymph node dissection as per standard of care) for metastatic disease in the neck in the opinion of the treating investigator\n3. Anatomically evaluable disease on chest CT (Computed Tomography) meeting one of the following criteria (obtained within 90 days of enrollment):\n\n   A. multiple (\\> 10) noncalcified solid pulmonary nodules visible on CT and\u002For B. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Identification of an activating RET gene alteration (fusion or mutation). The RET alteration result should be generated from a laboratory with specific certifications (depending on country requirement) that clearly denotes the presence of a RET alteration without known kinase domain resistance mutation\n5. Lansky\u002FKarnofsky performance status \\>50%\n6. Adequate Organ Function\n\n   A. Bone Marrow Function:\n   * Peripheral absolute neutrophil count (ANC) ≥1500\u002FµL\n   * Platelet count ≥ 100,000\u002FµL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\n   * Hemoglobin ≥ 9.0 g\u002FdL at baseline (may receive Red Blood Cell transfusions).\n\n   B. Adequate Renal Function: Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) ≥ 70 mL\u002Fmin\u002F1.73 m2 or a maximum serum creatinine based on age\u002Fgender.\n\n   C. Adequate Liver Function\n   * Bilirubin (sum of conjugated + unconjugated) \\\u003C \u002F = 1.5 x upper limit of normal (ULN) for age. Except participants with a documented history of Gilbert syndrome who must have a total bilirubin level of \\\u003C3.0X ULN\n   * Alanine aminotransferase (ALT) \\\u003C2.5X ULN OR \\\u003C5x ULN if the liver has tumor involvement. For the purpose of this study, the ULN for ALT is 45 U\u002FL.\n   * Serum albumin ≥ 2 g\u002FdL\n7. Patient must have normal serum potassium, calcium, and magnesium levels (may be receiving supplements)\n8. Men with partners of childbearing potential or women of childbearing potential must agree to use a highly effective contraceptive method during treatment with study drug and for 6 months following the last dose of study drug. Selpercatinib could impair fertility in males and females. Advise women not to breastfeed during treatment with selpercatinib and for 1 week following the final dose\n9. Women of childbearing potential must have a negative pregnancy test (serum or urine, consistent with local regulations) documented within 24 hours prior to treatment with study drug and at least monthly while on study treatment\n\nExclusion Criteria:\n\n1. No prior systemic therapy for thyroid cancer, including RET inhibitors. Note: prior 131I is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of selpercatinib and radioactive iodine to the fetus\u002Fneonate.\n3. Concurrent therapy: Patients currently receiving a strong CYP3A4 inducer or inhibitor are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided 14 days prior to treatment to the end of the study treatment.\n4. Patients with clinically significant active cardiovascular disease, Torsades de pointes, or history of myocardial infarction within 6 months prior to planned start of study treatment or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>470 msec.\n5. Have clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the drug.\n6. Are taking a concomitant medication that is known to cause QTc prolongation.\n7. Active hemorrhage or at significant risk for hemorrhage.\n8. Uncontrolled hypertension (blood pressure greater than 140\u002F90 in adults or greater than the 95% for height and gender in children). Use of anti-hypertensives to control blood pressure is permitted.","2 Years",{"count":227,"type":22},13,[26],"Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.",[231,32,126,232],"Differentiated Thyroid Cancer","Cancer, Thyroid",[234],"Thyroid Cancer","2026-07-23",{"date":237,"type":48},"2026-07-24",{"date":239,"type":48},"2024-07-29",{"date":241,"type":22},"2031-11-01",{"name":243,"class":83},"Children's Hospital of Philadelphia",5,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":252,"maxAge":92,"enrollmentInfo":253,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":195},"100648911","securing-access-to-innovative-molecules-in-oncology-and-hematology-for-children-adolescents-and-young-adults-100648911","NCT07727694","Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults","(SACHA)","Inclusion Criteria:\n\n* Age ≤ 25 at the time of inclusion in the study\n* Patient with a pediatric malignancy (solid tumor or leukemia), or other related condition\n* Patient not currently enrolled on any other trial for ongoing therapeutic purposes\n* Patient treated with compassionate use of experimental drugs or off-label administration use of anti-cancer medicines first approved in adults after 2007 in Europe\n* Patient discussed in a Pediatric multidisciplinary tumor boards (MDTB) to validate the inclusion in the SACHA study\n* Consent to participate by the patient or his\u002Fher legal representatives in the study if required by ta particular national jurisdiction\n\nExclusion Criteria:\n\n* Patient receiving the drug within a clinical trial.\n* Oral refusal to participate to the study, by the patient or his\u002Fher parents\u002Flegal representatives.","0 Years",{"count":254,"type":22},1600,"It involves collecting safety and efficacy data, under the actual conditions of use of off label and compassionate use medicines in children and adolescents approved in humans before 2007, using a validated tool (Ennov EDC) and relying on the network recognised pediatric hemato-oncology centers in Belgium and responsible for the organization of Pediatric National tumor boards which discuss each case of relapse in order to define the best therapeutic options.",[32],[258,259,260,261,262,263],"observational","data collection","childhood cancer","pediatric cancer","off label medication","CU medication","2026-07-22",{"date":266,"type":48},"2026-07-27",{"date":268,"type":22},"2026-07",{"date":270,"type":22},"2030-12-31",{"name":272,"class":83},"Universitaire Ziekenhuizen KU Leuven",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":155,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":84},"100573317","pharmacogenomic-testing-in-pediatric-hematologyoncology-patients-100573317","NCT06744712","Pharmacogenomic Testing in Pediatric Hematology\u002FOncology Patients","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information, and assent when applicable, from the participant, parent or legal guardian.\n2. Age ≤ 26 years at the time of consent.\n3. Newly diagnosed with a malignancy and planning to undergo anti-cancer therapy; or bone marrow transplant candidate with a non-malignant diagnosis who has not yet undergone myeloablative conditioning regimen.\n\nExclusion Criteria:\n\n1. Anti-cancer therapy has already been initiated. Note: Enrollment after initiation of intrathecal chemotherapy will be allowed.\n2. Previously received bone marrow transplant or planning to receive as part of initial upfront therapy for a malignant condition.\n3. Prior history of tissue or organ transplant.",{"count":280,"type":22},130,[69],"Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets. PGx testing uses an individual's genetic factors, such as single nucleotide polymorphisms (SNPs), to personalize therapy or dose a selection of medications. PGx testing has traditionally been used to test single genes, but there are now platforms allowing a panel of genes to be tested at once. To date there has not been a comprehensive screening of pediatric oncology patients to determine the prevalence of genetic variants that may affect anticancer therapy and supportive care medications. This study would allow us to summarize the frequency of clinically relevant gene-drug interactions and actionable genetic polymorphisms in pediatric oncology patients.",[32],[285,286],"Pharmacogenomic","Anti-Cancer Therapy","2026-07-21",{"date":264,"type":48},{"date":290,"type":22},"2026-09",{"date":292,"type":22},"2028-07",{"name":294,"class":83},"Wake Forest University Health Sciences",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":92,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":84},"100443753","lci-ped-nos-exer-001-exercise-in-pediatric-oncology-patients-100443753","NCT05058508","LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients","LCI-PED-NOS-EXER-001: Just Move. A Randomized Controlled Trial Investigating Exercise in Pediatric Oncology Patients","Inclusion Criteria:\n\n1. Ages 2-25 at time of consent\n2. Subject has newly diagnosed cancer per Investigator, and is planning to undergo chemotherapy for treatment of malignancy for at least 3 full cycles\n3. Ability of subject (and\u002For parent\u002Fguardian) to read and understand the English or Spanish language\n4. As determined and documented by the enrolling investigator, ability of the subject to understand and comply with study procedures for the entire length of the study\n5. Subject has newly diagnosed cancer per Investigator and is planning to undergo chemotherapy, immunotherapy, or other systemically delivered for treatment of malignancy. Subjects are allowed to be enrolled up to 21 days after initiating cancer treatment.\n6. Receiving oncologic care at Levine Children's Cancer and Blood Disorders Clinic.\n7. Subject is anticipated to receive at least 3 full cycles of chemotherapy or other systemic cancer treatment.\n8. Not participating in another clinical trial that precludes participating in additional nondrug clinical trials.\n\nExclusion Criteria:\n\n1. Known cardiac dysfunction that, in the opinion of the investigator, would be unsafe for the child to participate in the exercise program\n2. Any other uncontrolled intercurrent illness\u002Fmedical condition or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or would be considered unsafe for the child to participate as determined by the Investigator.\n3. Recent (within 4 weeks of enrollment) or planned surgery that will result in prolonged limited mobility not amendable to exercise modifications per investigator discretion\n4. Primary CNS Tumor\n5. Osteosarcoma",{"count":303,"type":22},60,[69],"The purpose of this study is to see if there are physical and emotional benefits to participating in a structured exercise regimen for those who are ages 2-25, are newly diagnosed with a blood or solid tumor cancer, and are currently undergoing or will begin cancer treatment.",[32],[308,309],"Exercise","Pediatric Oncology",{"date":264,"type":48},{"date":312,"type":48},"2024-03-11",{"date":314,"type":22},"2027-11",{"name":294,"class":83},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":84},"100435316","phase-2-immune-function-and-response-to-vaccination-after-cancer-therapy-in-pediatric-patients-100435316","NCT04948619","Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients","Immune Function and Response to Vaccination Following Completion of Cancer Directed Systemic Therapy in Pediatric Patients With Cancer","Inclusion Criteria:\n\n1. Written informed consent, HIPAA authorization for release of personal health information, and assent, when applicable from the subject, parent, or legal guardian.\n2. Age greater than or equal to 2 years and less than 22 years at the time of consent\n3. Lansky\u002FKarnofsky Performance Status of greater than 50 (ECOG less than 2) within 60 days prior to date of enrollment\u002Frandomization\n4. Histological or cytological confirmation of any malignancy treated by the Pediatric Oncology team of Levine Children's Hospital\n5. History of any malignant diagnosis treated with at least one cycle of cancer directed systemic therapy\n6. Must be no more than 60 days from last dose of cancer directed systemic therapy at time of enrollment\u002Frandomization\n7. As determined by the enrolling physician, ability of the subject and parent\u002Fcaregiver to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n1. Malignant disease treated with observation, surgery, or radiotherapy alone\n2. Known coexisting immunodeficiency\n3. Subjects with normal baseline titers for all investigated vaccines\n4. Known pregnancy\n5. Documented previous severe allergic reaction to any vaccine or component of a vaccine\n6. Documented current\u002Factive, severe infection, as determined by the investigator","21 Years",{"count":325,"type":22},64,[26],"Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superior for regaining immunity against potentially serious infections in survivors.",[32],[309,330],"Vaccine",{"date":235,"type":48},{"date":333,"type":48},"2022-08-08",{"date":335,"type":22},"2030-10",{"name":294,"class":83},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":63,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":84},"100609726","food-is-medicine-in-survivorship-examining-the-feasibility-and-impact-of-a-scalable-food-delivery-and-culinary-medicine-program-foodiis-among-pediatric-cancer-survivors-and-their-families-100609726","NCT07218328","Food is Medicine in Survivorship: Examining the Feasibility and Impact of a Scalable Food Delivery and Culinary Medicine Program (FoodiiS) Among Pediatric Cancer Survivors and Their Families","Inclusion Criteria:\n\n* Parents\u002Fguardians of school-aged (5-12 years) pediatric cancer survivors.\n* Have children that are within five years of having completed active treatment.\n* Self-report having internet access.\n* Self-report as being able to speak and read English.\n* Willing to complete study assessments.\n\nExclusion Criteria:\n\n* Parents of pediatric cancer survivors over 12 years of age.\n* Unwilling or unable to complete study assessments.\n* Self-report to not speak English.",{"count":344,"type":22},21,[69],"The goal of this research study is to learn if the FoodiiS-Kids intervention is useful to parents and guardians of pediatric cancer survivors.",[32],"2026-07-15",{"date":350,"type":48},"2026-07-17",{"date":352,"type":22},"2026-12-30",{"date":354,"type":22},"2029-07-01",{"name":356,"class":83},"M.D. Anderson Cancer Center",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":63,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100461872","testing-esccip-an-ehealth-psychosocial-intervention-for-english-and-spanish-speaking-parents-of-children-with-cancer-100461872","NCT05294302","Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer","A Randomized Controlled Trial of eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer","Inclusion Criteria:\n\n* Participants must be the parent or primary caregiver of a child (ages 0 - 18 years old) diagnosed with cancer.\n* Participants must be able to speak and read English or Spanish.\n* Participants must have access to the internet through a computer or mobile device (e.g., smartphone, tablet).\n\nExclusion Criteria:\n\n* PCCC are ineligible to participate if their child is not expected to live longer than six months from the time of potential recruitment",{"count":365,"type":22},350,[69],"It is critical to provide accessible evidence-based psychosocial support to parents and caregivers of children with cancer (PCCC) in order to mitigate individual and family-level psychosocial risks. This effectiveness trial evaluates an eHealth intervention for English- and Spanish-speaking (PCCC) with study endpoints focused on decreasing negative psychosocial sequelae (acute distress, posttraumatic stress, and anxiety) and improving coping abilities (coping self-efficacy, cognitive coping strategies). The long-term goal of this research program is to sustain and disseminate an effective, scalable, high-reach, and cost-effective intervention to provide crucial support to PCCC across the pediatric cancer trajectory.",[32],[370,261,371,372],"eHealth","parents","psychosocial intervention",{"date":350,"type":48},{"date":375,"type":48},"2023-04-14",{"date":377,"type":22},"2026-12-31",{"name":379,"class":83},"Nemours Children's Clinic",3,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":203,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":407},"100271443","phase-1-european-proof-of-concept-therapeutic-stratification-trial-of-molecular-anomalies-in-relapsed-or-refractory-tumors-100271443","NCT02813135","European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","ESMART","Inclusion Criteria:\n\n1. Patients must be diagnosed with a haematologic or solid tumor malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists.\n2. Age \\\u003C 18 years at inclusion; patients 18 years and older may be included after discussion with the sponsor if they have a pediatric recurrent\u002Frefractory malignancy.\n3. Patient must have had advanced molecular profiling (i.e. WES\u002FWGS +\u002F- RNAseq) of their recurrent or refractory tumor i.e. at the time of disease progression\u002Frelapse; exceptionally patients with advanced molecular profiling at diagnosis may be allowed.\n4. Evaluable or measurable disease as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1, RANO criteria for patients with HGG, INRC criteria for patients with NB, Leukemia criteria, etc.).\n5. Patients with relapsed or refractory leukemia are eligible for this study.\n6. Performance status: Karnofsky performance status (for patients \\>12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n7. Life expectancy ≥ 3 months\n8. Adequate organ function:\n\n   Hematologic criteria (Leukemia patients are excluded from hematological criteria):\n   * Peripheral absolute neutrophil count (ANC) ≥ 1000\u002FμL(unsupported)\n   * Platelet count ≥ 100,000\u002FμL (unsupported)\n   * Hemoglobin ≥ 8.0 g\u002FdL (transfusion is allowed)\n\n   Cardiac function:\n   * Shortening fraction (SF) \\>29% (\\>35% for children \\\u003C 3 years) and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).\n   * Absence of QTc prolongation (QTc \\> 450 msec on baseline ECG, using the Fridericia correction \\[QTcF formula\\]) or other clinically significant ventricular or atrial arrhythmia.\n\n   Renal and hepatic function:\n   * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age\n   * Total bilirubin ≤ 1.5 x ULN\n   * Alanine aminotransferase (ALT)\u002Fserum glutamic pyruvic transaminase (SGPT) ≤ 2,5 x ULN; aspartate aminotransferase (AST)\u002Fserum glutamic oxaloacetic transaminase\u002FSGOT ≤ 2,5 x ULN except in patients with documented tumor involvement of the liver who must have AST\u002FSGOT and ALT\u002FSGPT ≤ 5 x ULN.\n9. Able to comply with scheduled follow-up and with management of toxicity.\n10. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months (7 months for arm J) after the last study treatment administration. Acceptable contraception are defined in CTFG Guidelines \"Recommendations related to contraception and pregnancy testing in clinical trials\"\n11. For all oral medications patients must be able to comfortably swallow capsules (except for those for which an oral solution is available); nasogastric or gastrostomy feeding tube administration is allowed only if indicated.\n12. Written informed consent from parents\u002Flegal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.\n13. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.\n\nExclusion Criteria:\n\n1. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients on stable doses of corticosteroids for at least 7 days prior to receiving study drug may be included.\n2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).\n3. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality, unstable ischemia,congestive heart failure within 12 months of screening)\n4. Active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n5. Presence of any ≥ CTCAE grade 2 treatment-related toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.\n6. Systemic anticancer therapy within 21 days of the first study dose or 5 times its half-life, whichever is less.\n7. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks of the first study drug dose\n8. Allogeneic stem cell transplant within 3 months prior to the first study drug dose. Patients receiving any agent to treat or prevent graft-versus host disease (GVHD) post bone marrow transplant are not eligible for this trial.\n9. Radiotherapy (non-palliative) within 21 days prior to the first dose of drug (or within 6 weeks for therapeutic doses of MIBG or craniospinal irradiation).\n10. Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.\n11. Currently taking medications with a known risk of prolonging the QT interval or inducing Torsades de Pointes (Refer to Appendix 8).\n12. Currently taking medications that are mainly metabolized by CYP3A4\u002F5, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 and have a low therapeutic index that cannot be discontinued at least 7 days or 5 x reported elimination half-life prior to start of treatment with any of the investigational drugs and for the duration of the study (Refer to Appendix 9).\n13. Known hypersensitivity to any study drug or component of the formulation.\n14. Pregnant or nursing (lactating) females.\n15. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug.",{"count":389,"type":22},472,[25,26],"This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).\n\nThe aims of the trial are:\n\n1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and\u002For a relevant combination in a pediatric population, to document its tolerability and\n2. To explore first signals of activity in a molecularly enriched study population.",[32],[182,394,395,396,397],"Adolescents","Young adults","Recurrent malignancies","Refractory malignancies","2026-07-09",{"date":400,"type":48},"2026-07-10",{"date":402,"type":48},"2016-08-03",{"date":404,"type":22},"2031-02",{"name":406,"class":83},"Gustave Roussy, Cancer Campus, Grand Paris",23,{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":423,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":244},"100564996","phase-1-a-phase-i-first-in-human-study-of-cba-1205-anti-dlk1-monoclonal-antibody-in-patients-with-advanced-solid-tumors-hepatocellular-carcinoma-hcc-melanoma-and-pediatric-cancer-100564996","NCT06636435","A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer","A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors.","Inclusion Criteria:(Part 1-4)\n\n* Patients who provide voluntary written informed consent to participate in the study\n* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of≤1\n* Patients with preserved renal function as evidenced by laboratory data obtained within 7 days before enrollment (creatinine: ≤ ULN ×1.5)\n* Patients who meet the following laboratory criteria of bone marrow function as evidenced by laboratory data obtained within 7 days before enrollment: Neutrophil count;≥1500\u002FμL, Platelet count; ≥75000\u002FμL, Hemoglobin;≥9.0 g\u002FdL.\n* Patients having Solid Tumors with no standard therapy available or refractory or intolerable to standard therapy (Part2, 3)\n* Patients with Child-Pugh A or B (Part2, 3)\n* Patients with Malignant Melanoma who are refractory or intolerant to standard therapy (Part 4)\n\nInclusion Criteria:(Part 5)\n\n* Patients who provide voluntary written informed consent to participate in the study from both the subject (if aged 16 years or older) and their legal representatives\n* Japanese patients aged 2 years or older and under 20 years at the time of informed consent\n* Patients with a Lansky Performance Status (LPS) of ≥70 (for patients aged 15 years or younger) or a Karnofsky Performance Status (KPS) of ≥70 (for patients aged 16 years or older)\n* Patients with preserved renal function as evidenced by laboratory data obtained within 7 days before enrollment (eGFR ≥60 mL\u002Fmin\u002F1.73 m²)\n* Pediatric patients with cancers with no standard therapy available or refractory or intolerable to the standard therapy\n\nExclusion criteria: (Part1-5)\n\n* Patients who have undergone major surgery within 28 days before enrollment\n* Patients who have received anticancer treatment with surgical therapy, radiation therapy, and\u002For drug therapy within 14 days before enrollment\n* Patients who have received anticancer treatment with immune checkpoint inhibitor, etc. within 28 days before enrollment\n* Patients with Grade 2 or higher concurrent disease or prior therapy-related toxicity\n* Patients who have received any other investigational product within 28 days before enrollment\n* Patients with current or previous inadequately controlled or clinically significant cardiac disease\n* Patients who, in the opinion of the investigator or subinvestigator, is not appropriate",{"count":416,"type":22},66,[25],"In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5). The purpose of this FIH study is to evaluate the safety and tolerability profile of CBA-1205.",[420,421,422,32],"Solid Tumors","Hepatocellular Carcinoma (HCC)","Malignant Melanoma",[424,425,426,427,428,429,430,431,32],"DLK1","First in human","Phase I","Antibody","solid tumor","Hepatocellular Carcinoma","CBA-1205","Melanoma","2026-06-15",{"date":434,"type":48},"2026-06-17",{"date":436,"type":48},"2020-06-01",{"date":438,"type":22},"2027-06-30",{"name":440,"class":55},"Chiome Bioscience Inc.",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":203,"enrollmentInfo":447,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":84},"100468784","response-to-influenza-vaccination-in-pediatric-oncology-patients-100468784","NCT05384288","Response to Influenza Vaccination in Pediatric Oncology Patients","Inclusion Criteria:\n\n* Patient ≤ 18 years old at the time of consent receiving care at St. Jude Children's Research Hospital\n* Diagnosed with a hematological malignancy\n* Eligible to receive the current seasonal influenza vaccine\n\nExclusion Criteria:\n\n• Previously received at least one dose of the current seasonal influenza vaccine.",{"count":448,"type":22},150,"Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity in the form of lower respiratory tract infection (LRTI) and mortality relative to otherwise healthy patients. The study participants have been diagnosed with a hematological malignancy and are eligible to receive the current seasonal influenza (Flu) vaccine.\n\nPrimary Objective\n\n* To determine the feasibility of opening a longitudinal prospective study of IIV immunogenicity in pediatric leukemia patients.\n* To describe the immunogenicity, as measured by the development of cell- and\u002For antibody-mediated influenza specific responses 3 to 5 weeks following vaccination, in a cohort of pediatric leukemia patients.\n\nSecondary Objectives\n\n* To describe whether an immune response, as measured by development of cell- and\u002For antibody-mediated influenza specific responses, is detectable 1-2 weeks following vaccination in a cohort of pediatric leukemia patients.\n* To describe the durability of immunogenicity by measuring cell - and antibody- mediated influenza specific responses at 6 months and 1 year following vaccination in a cohort of pediatric leukemia patients.\n\nExploratory Objectives\n\n* To estimate the clinical effectiveness of influenza vaccine in this cohort by monitoring for the development of clinical diagnosis of influenza in the cohort of enrolled pediatric oncology patients.\n* To correlate results of immune cell frequency in blood, as measured by complete blood count with differential, with development of an immune response to IIV.",[451,32,452],"Hematologic Malignancy","Transplant-Related Cancer",[454],"Influenza infection","2026-06-11",{"date":457,"type":48},"2026-06-12",{"date":459,"type":48},"2022-10-07",{"date":461,"type":22},"2029-12-01",{"name":463,"class":83},"St. Jude Children's Research Hospital",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":252,"maxAge":323,"enrollmentInfo":471,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":380},"100643783","caya-cancer-prospective-cohort-study-100643783","NCT07632014","CAYA Cancer Prospective Cohort Study","Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Prospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries.","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be included in this study:\n\n1. Age 0 to 21 years at study enrollment.\n2. Diagnosed with cancer and receiving active treatment or undergoing follow-up at the participating sites.\n\n   a. Note: Patients seen solely for consultation or diagnostic evaluations without subsequent treatment and those who have been off treatment for more than 5 years and are seen only for survivorship follow-up are not considered as meeting this criterion.\n3. Willingness to provide informed consent\u002Fassent. For minors incapable of providing assent, or individuals unable to provide consent, consent must be obtained from a legal representative and in accordance with local requirements.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria must be excluded from this study:\n\n1\\. Any medical or psychological condition that, in the investigator's opinion, might compromise the ability of the patient to provide assent\u002Finformed consent\u002Fassent.",{"count":472,"type":22},6000,"Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited. As a result, patients in these settings may experience higher rates of treatment complications, interruptions, and poorer outcomes compared with those in high-income countries (HICs).\n\nThis is a prospective, multicenter observational study that will follow children, adolescents, and young adults(CAYAs) with cancer who are receiving routine care at participating hospitals in low - and middle - income countries(LMICs). The study does not involve experimental treatments or changes to standard medical care. Information will be collected from medical records and from questionnaires that address access to care and social factors affecting treatment.\n\nBy describing treatment outcomes and the challenges patients and families face during cancer care, this study aims to provide data that can help inform future efforts to improve access to care and cancer outcomes in resource-limited settings.",[126,32,475,476],"Lymphoblastic Lymphoma (LBL)","Acute Lymphoblastic Leukemia (ALL)",[478,479,480,481,482,483,484,485,486,487,488],"Children, Adolescents, and Young Adults (CAYA)","Low- and middle-income countries (LMIC)","Observational Study","Cancer Outcomes","Treatment-Related Toxicity","Treatment Failure","Treatment Abandonment","Diagnostic Delay","Socioeconomic Factors","High-income countries (HICs)","Central Nervous System(CNS)","2026-06-03",{"date":491,"type":48},"2026-06-08",{"date":493,"type":48},"2025-11-11",{"date":495,"type":22},"2032-11-11",{"name":497,"class":83},"Resonance, Inc.",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":84},"100448520","post-mortem-tissue-donation-of-pediatric-tumor-tissues-and-cells-100448520","NCT05120518","Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells","Inclusion Criteria:\n\n* Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology)\n* Signed consent for post mortem tissue donation and autopsy\n\nExclusion Criteria:\n\n* Signed consent for post mortem tissue donation and autopsy not obtained",{"count":448,"type":22},"The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).",[32],"2026-06-02",{"date":489,"type":48},{"date":510,"type":48},"2019-08-14",{"date":512,"type":22},"2029-08-14",{"name":514,"class":83},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":84},"100172432","life-cancer-survivorship-database-for-pediatric-cancer-100172432","NCT01518400","LIFE Cancer Survivorship Database for Pediatric Cancer","A Research Database for Survivors of Childhood Cancer","Inclusion Criteria:\n\n* Been diagnosed with cancer or similar disease\n* Been diagnosed with cancer at 21 years of age or younger\n* Be currently off treatment and disease free",{"count":94,"type":22},"The purpose of this study is to develop a mechanism for utilizing the comprehensive clinical database of childhood cancer survivors at Childrens Hospital Los Angeles (CHLA) for research purposes. Using clinical information obtained from follow-up visits of childhood cancer survivors, the database will focus on interventions to improve health status and health-related quality of life in childhood cancer survivors. This study allows for establishment and analyses of a research database for LIFE survivors by the investigators listed herein. Over the last three decades, there has been marked improvement in survival following childhood cancer, with 5-year survival rates now approaching 80%. However, the use of cancer therapy at an early age can result in complications that may not be apparent until years later as the child matures. These resulting complications, called late effects, are principally related to the specific therapy employed and the age of the child at the time the therapy was administered. Late effects may affect virtually every body system and substantially impair quality of life. As many as two-thirds of childhood cancer survivors develop at least one late effect as a result of treatment, and approximately one-third have a late effect classified as severe or life threatening.",[32],[32,526,527,528],"Cancer Late Effects","Cancer Survivor","Cancer Survivorship",{"date":530,"type":48},"2026-06-04",{"date":532,"type":4},"2009-02",{"date":534,"type":22},"2050-12",{"name":536,"class":83},"Children's Hospital Los Angeles",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":63,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":563},"100520340","multisite-implementation-of-comprendo-100520340","NCT06055296","Multisite Implementation of COMPRENDO","Multisite Implementation of COMPRENDO (ChildhOod Malignancy Peer REsearch NavigatiOn) to Improve Participation of Hispanic Children in Cancer Clinical Trials","COMPRENDO","Non-Stakeholder\u002FStakeholder Parent Eligibility criteria: A parent\u002Flegal guardian who has a Hispanic child aged 0 to 17y with a new diagnosis of cancer, has a child who is eligible for a therapeutic cancer clinical trial, will participate in an informed consent discussion for the therapeutic clinical trial, understands written and spoken English or Spanish, and has signed the consent form for the proposed COMPRENDO study. Participants will not be eligible if their child has second malignancy\u002Frelapse, was diagnosed at an outside institution, has potential transfer of care, was previously on a clinical trial\n\nStakeholder Clinician\u002FNavigator\u002FAdministrator Clinicians, navigators and administrators who work at each site, are involved in treating pediatric patients and who are involved in the informed consent conference for clinical trials.",{"count":546,"type":22},450,[69],"COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel implementation factors that can inform real-world setting implementation. This study will test the impact of COMPRENDO, a peer-navigation intervention, vs. usual care on accrual to childhood cancer therapeutic clinical trials and parental informed consent outcomes. COMPRENDO will be delivered by trained peer navigators in 4 visits. A mixed methods (surveys, individual interviews) implementation evaluation will examine implementation factors that can inform the use of peer navigation in clinical practice, integrating data from clinicians, navigators, administrators, and parents pre and post the RCT.",[32],[551,552,553,554],"Research Literacy","Cancer Disparities","Minority Clinical Trial Accrual","Patient Navigation","2026-06-01",{"date":489,"type":48},{"date":558,"type":48},"2024-01-11",{"date":560,"type":22},"2028-06-30",{"name":562,"class":83},"University of California, San Diego",4,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":91,"maxAge":203,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":84},"100434220","virtual-reality-for-children-in-radiotherapy-rever-100434220","NCT04934293","Virtual Reality for Children in Radiotherapy (REVER)","REVER","Inclusion Criteria:\n\n* Patient treated at the Antoine LACASSAGNE Center for treatment by proton therapy\n* Age ≥ 7 years old and ≤ 18 years old\n* Patient, and parents for minor children, having read the information notice and signed the informed consent,\n* Patient with social security coverage.\n\nExclusion Criteria:\n\n* Age \\\u003C 7 years old and \\> 18 years old,\n* Patient under general anesthesia,\n* Patient suffering from wounds or infections in the head, deemed incompatible with the use of the helmet by the investigator,\n* Patient suffering from respiratory problems,\n* Patient suffering from a high level of claustrophobia,\n* Patient followed for a psychiatric pathology,\n* Patient suffering from unbalanced epilepsy,\n* Patient suffering from visual (binocular vision) and \u002F or hearing disorders preventing the use of virtual reality,\n* Patient whose head circumference is insufficient for the use of the helmet, deemed incompatible with the use of the helmet by the investigator,\n* Patient treated by radio chemotherapy.",{"count":572,"type":22},47,[69],"For a young patient, the conditions of proton therapy treatment can be stressful. Adjusting the environment can be a source of avoiding this physical and psychological discomfort impacting the quality of treatment.\n\nA fixed, long, uncomfortable position is the main cause of stress, already present due to the cancerous therapeutic course. It extends the positioning time. For the patient and the optimization of his treatment, solutions must be sought.\n\nRelaxation in virtual reality is efficient, simple and non-medicinal and could reduce stress in children and allow irradiation in very good conditions.\n\nWe will assess the effectiveness of the virtual reality session using objective (placement time, helmet tolerance) and subjective (perceived anxiety via a dedicated questionnaire) criteria. This is the first pediatric virtual reality study, supported by the French Group of Pediatric Radiotherapists, to reduce anxiety in radiotherapy.\n\nMultiple benefits from this pilot study are expected, such as improved reception conditions, treatment parameters and better acceptance of proton therapy sessions.",[576,577,32],"Virtual Reality","Proton Therapy","2026-05-27",{"date":580,"type":48},"2026-05-29",{"date":582,"type":48},"2021-08-02",{"date":584,"type":22},"2027-02",{"name":586,"class":83},"Centre Antoine Lacassagne",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":611},"100475241","phase-1-safety-and-efficacy-of-cyclophosphamide-sorafenib-bevacizumab-and-atezolizumab-in-pediatric-solid-tumor-patients-100475241","NCT05468359","Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C 30 years at the time of enrollment on study.\n* Willingness to enroll on the St. Jude Molecular Analysis of Solid Tumors (MAST) study.\n* Diagnosis\n* Part 1: Patients with refractory or recurrent (relapsed) solid tumors accessible by biopsy for which there is no standard therapy are eligible.\n* Part 2: Patients with one of the following diagnoses:\n* Biopsy accessible refractory or recurrent (relapsed) hepatocellular carcinoma\n* Biopsy accessible refractory or recurrent (relapsed)or FL-HCC, DSRCT or non-CNS MRT.\n* Performance level: Karnofsky \\> 50 for patients \\> 16 years of age and Lansky \\> 50 for patients \\\u003C 16 years of age (See Appendix III). Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n* Disease status: Patients must tumors that are unresectable and have either measurable or evaluable disease that is accessible by biopsy\n* Organ function: Must have adequate organ and bone marrow function as defined by the following parameters:\n* Patients with solid tumor not metastatic to bone marrow:\n\n  * Peripheral absolute neutrophil count (ANC) \\>1,000\u002Fmm3\n  * Platelet count \\> 75,000\u002Fmm3 (no transfusion within 7 days of enrollment)\n  * Hemoglobin \\> 8 g\u002FdL (with or without support)\n* Patients with solid tumor metastatic to bone marrow will be eligible for study but not evaluable for hematologic toxicity. These patients must not be known to be refractory to red cell or platelet transfusions. At least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity. If dose limiting hematologic toxicity is observed at any dose level, all subsequent patients enrolled must be evaluable for hematologic toxicity.\n* Adequate renal function defined as serum creatinine based on age as shown in Table 1, or creatinine clearance or radioisotope GFR 50 ml\u002Fmin\u002F1.73m2 (GFR 40 ml\u002Fmin\u002F1.73m2 if \\\u003C 2 years of age).\n* Adequate hepatic function defined as total bilirubin \\\u003C 5x upper limit of normal (ULN) and AST\u002FALT \\\u003C 3 x ULN for age.\n* Adequate cardiac function defined as shortening fraction \\> 28% OR ejection fraction of ≥ 47% by echocardiogram.\n* Adequate blood clotting defined as PT\u002FPTT \\\u003C 1.2 x ULN without factor replacement products for 7 days\n* Females of childbearing potential and males able to father a child must be willing to practice acceptable methods of birth control to prevent pregnancy during the study and for at least 5 months after last dose of therapy.\n* Patients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study:\n* Myelosuppressive chemotherapy: Patient has not received myelosuppressive chemotherapy within 1 weeks of enrollment onto this study (within 2 weeks of estimated therapy start date) (4 weeks if prior nitrosourea).\n* Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.\n* Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur.\n* Monoclonal antibodies: At least 14 days (at least 21 days from therapy start date) must have elapsed since the completion of therapy with a monoclonal antibody.\n* Radiotherapy: At least 1 week (2 weeks from estimated therapy start date) must have elapsed since any irradiation; at least 5 weeks (at least 6 weeks from estimated therapy start date) must have elapsed since craniospinal RT or substantial bone marrow irradiation.\n* Chemoembolization: at least 21 days (28 days from estimated therapy start date) must have elapsed since the completion of chemoembolization\n* Radioembolization: at least 21 days (28 days from estimated therapy start date) must have elapsed since the completion of radioembolization\n* Cardiac disease or hypertension: Patients must not have a history of myocardial - infarction, severe or unstable angina, or severe peripheral vascular disease. Hypertension must be well controlled on stable doses of medication for at least two weeks.\n* Female participant who is post-monarchal must have a negative urine or serum pregnancy test.\n* Life expectancy of at least 8 weeks\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Currently receiving other investigational drugs.\n* Unwilling or unable to comply with the safety monitoring requirements of this protocol.\n* Tumor not safely accessible by biopsy\n* Inability or unwillingness of research participant or legal guardian \u002F representative to give written informed consent.\n* Surgical procedures and serious or non-healing wounds: patients with a documented, chronic non-healing wound, ulcer, or bone fracture or history of a major surgical procedure or significant traumatic injury within 28 days prior to beginning therapy are excluded due to preclinical evidence supporting the potential for delayed wound healing.\n* Minor surgical procedures for minimally invasive biopsies will be allowed. For minor surgeries, the wound must be healed, and 7 days elapsed since surgery. For procedures such as the placement of an indwelling IV catheter, it is recommended that bevacizumab be postponed for at least 24 hours after the procedure.\n* Thrombosis: Patients must not have a deep venous or arterial thrombosis (including pulmonary embolism) within the last three months prior to study entry and must not have a known thrombophilic condition (i.e., protein S, protein C or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome).","30 Years",{"count":325,"type":22},[25,26],"This is a phase I\u002FII study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies (Part 1), and then evaluate the response rate of this combination in children, AYA with relapsed or refractory fibrolamellar carcinoma (FLC) and other rare solid malignancies (Part 2).\n\nPrimary Objectives Part 1\n\n* To establish the safety associated with the administration of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors\n* To determine if sorafenib systemic exposure can be successfully targeted to an AUC between 20 and 55 hr·µg\u002FmL by Day 21 of cycle 1 in 60% of evaluable patients, when given in combination with cyclophosphamide, bevacizumab, and atezolizumab in children and AYA with relapsed or refractory solid tumors\n\nPart 2\n\n* To evaluate the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory FLC following two cycles of therapy\n* To determine if the use of PK-guided sorafenib dosing to maintain a systemic exposure between 20 and 55 reduces the interpatient pharmacokinetic variability of sorafenib and the incidence of sorafenib- induced skin toxicities in children and AYA with relapsed or refractory FLC and other rare solid tumors\n\nParts 1 \\& 2\n\n* To determine if the combination of cyclophosphamide, PK-guided sorafenib and atezolizumab will result in increased intratumoral T-cell infiltration of CD8+C45RO+ cells between baseline and following two courses of therapy in pediatric children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n* To characterize the pharmacokinetics of atezolizumab in combination with cyclophosphamide, PK-guided sorafenib and bevacizumab in children and AYA with relapsed or refractory solid tumors\n* To assess the feasibility of performing contrast enhanced ultrasound and explore the correlation between quantitative CEUS parameters and clinical response.\n\nSecondary Objectives\n\nPart 1\n\n• To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n\nPart 2\n\n• To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory FLC, HCC, desmoplastic small round cell tumor, malignant rhabdoid tumor, and other rare solid tumors following two cycles of therapy\n\nParts 1\\&2\n\n* To describe the number of children with liver tumors, initially judged unresectable at diagnosis, that can have their primary tumor resected after treatment with oral cyclophosphamide and sorafenib with intravenous bevacizumab and atezolizumab\n* To describe changes in immune cells in the peripheral blood at periodic times before and after treatment with this combination chemoimmunotherapy\n* To describe the PFS, EFS, and OS in patients treated with the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab, and atezolizumab in patients with relapsed or refractory FLC, DSRCT, MRT, HCC and other rare solid tumors",[599,429,600,32,601,602],"Refractory Solid Tumor","Malignant Solid Tumor","Pediatric Solid Tumor","Fibrolamellar Carcinoma","2026-05-18",{"date":605,"type":48},"2026-05-19",{"date":607,"type":48},"2022-11-07",{"date":609,"type":22},"2037-06",{"name":463,"class":83},2,{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":203,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":624,"conditions":625,"keywords":629,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":642,"leadSponsor":644,"locationsCount":563},"100639005","phase-4-early-discontinuation-of-antibiotics-in-paediatric-high-risk-febrile-neutropenia-100639005","NCT07590648","Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia","Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients (e-STOP 2)","E-STOP2","Inclusion Criteria:\n\n1. Male and female patients ≤18 years of age expected to develop prolonged neutropenia (\\>7 days), with:\n\n   * Acute myeloblastic leukaemia at any phase of chemotherapy\n   * Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases\n   * Biphenotypic leukaemia at any phase of chemotherapy\n   * Lymphoblastic lymphoma in induction and consolidation phases\n   * B-cell and anaplastic lymphoma receiving high-intensity chemotherapy\n   * Solid tumours receiving high-intensity chemotherapy\n   * Relapsed leukaemia at any phase of treatment\n2. Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) \\\u003C500 neutrophils\u002Fmm³, or expected to fall below this value within the next 48-72 hours.\n3. Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days\u002Fweek for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study).\n4. Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following:\n\n   * CRP \\\u003C9 mg\u002FdL\n   * PCT \\\u003C0.5 ng\u002FmL\n   * Absence of hypotension\n5. No microbiologically documented bacterial infection 48-72 hours after the FN episode.\n6. Good clinical evolution 48-72 hours after the FN episode, defined as:\n\n   * Afebrile for \\>48 hours (axillary temperature \\\u003C38°C)\n   * Haemodynamically stable\n   * Stable paediatric early warning score (PEWS)\n7. CRP \\\u003C5 mg\u002FdL, or CRP \\\u003C9 mg\u002FdL and PCT \\\u003C0.5 ng\u002FmL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode).\n8. ANC \\\u003C500 neutrophils\u002Fmm³ at the time of randomisation.\n9. Signed informed consent from the patient and\u002For parent(s)\u002Flegal representative(s).\n10. Patient and\u002For parent(s)\u002Flegal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study.\n11. Patient and\u002For parent(s)\u002Flegal representative(s) must be considered reliable and capable of adhering to the protocol.\n\nExclusion Criteria:\n\n1. Antibiotic treatment at the time of the FN episode different from that used prophylactically.\n2. Empirical antibiotic treatment different from that recommended in international guidelines.\n3. Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death).\n4. Active participation in the same study at the onset of the current FN episode.\n5. Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results.\n6. Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol.\n7. Female patients who are pregnant or breastfeeding",{"count":621,"type":22},136,[623],"PHASE4","The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker levels 48-72 hours after the episode.\n\nThe main questions it aims to answer are:\n\nIs early discontinuation of antibiotics as safe as the standard strategy in terms of preventing invasive bacterial infections (such as sepsis, microbiologically documented infection, ICU admission, or death)? Does this strategy reduce the number of days on antibiotics without increasing infection-related complications?\n\nResearchers will compare early antibiotic discontinuation with the standard care strategy to see whether the early-stop approach provides similar safety while reducing antibiotic exposure.\n\nParticipants will:\n\nReceive standard initial antibiotic therapy for febrile neutropenia. Undergo clinical and biomarker evaluations (including CRP and PCT).\n\nBe randomly assigned to:\n\nExperimental group: early discontinuation of antibiotics, or Control group: continuation of the standard antibiotic strategy.\n\nBe followed for 28 days after randomisation to monitor safety outcomes and treatment effects.",[626,32,627,420,628],"Febrile Neutropenia (FN)","Hematologic Malignancies","Invasive Bacterial Infection",[630,309,627,420,628,631,632,633,634,635,636,637],"Febrile Neutropenia","Antibiotic Discontinuation","Antibiotic Stewardship","Biomarkers (CRP, PCT, IL-8)","Early Stop Strategy","Randomized Clinical Trial","Non-Inferiority Trial","Neutropenia","2026-05-13",{"date":640,"type":48},"2026-05-15",{"date":555,"type":22},{"date":643,"type":22},"2028-07-01",{"name":645,"class":83},"Hospital Universitari Vall d'Hebron Research Institute",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":64,"maxAge":653,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":655,"briefSummary":656,"conditions":657,"keywords":659,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":84},"100638892","telerehabilitation-based-dance-therapy-in-pediatric-cancer-100638892","NCT07596745","Telerehabilitation-Based Dance Therapy in Pediatric Cancer","Effects of Telerehabilitation-Based Dance Therapy on Motor Proficiency, Quality of Life, Participation, and Motivation in Pediatric Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 6-14 years diagnosed with a hematological malignancy or solid tumor by a pediatric oncology specialist.\n* Currently undergoing treatment or within 6 months after completion of treatment (for hematological malignancies: during maintenance therapy or ≤6 months post-treatment; for solid tumors: during treatment or ≤6 months post-treatment).\n* Medically stable and cleared by the treating clinical team to participate in moderate physical activity\u002Fdance therapy.\n* Able to stand independently and perform movements without assistive devices.\n* Access to a digital device (smartphone, tablet, or computer) equipped with a camera, audio capability, and a stable internet connection.\n* Parent\u002Fguardian able to read and write in Turkish.\n* Written informed consent from the parent\u002Fguardian and assent from the child (as appropriate for age).\n\nExclusion Criteria:\n\n* Pre-existing genetic, neurological, developmental, or motor disorders diagnosed prior to cancer diagnosis that may affect motor performance.\n* Medical contraindications to exercise (e.g., unresolved fractures, severe avascular necrosis, recent bone marrow transplantation, or other conditions restricting physical activity as determined by the treating physician).\n* Inability to maintain stable internet connectivity required for telerehabilitation sessions.\n* Previous structured dance therapy participation within the last 6 months.","14 Years",{"count":21,"type":22},[69],"Childhood cancer requires prolonged and intensive treatment, resulting in significant biopsychosocial challenges for affected children and their families. During and following treatment, children frequently experience impairments in fine and gross motor skills, reduced physical capacity, emotional difficulties, and decreased participation in daily activities. Within the framework of the International Classification of Functioning, Disability and Health for Children and Youth (ICF-CY), these impairments in body structure and function may negatively influence activity, participation, and overall quality of life.\n\nDance therapy is a holistic rehabilitation approach that integrates rhythm, structured movement, and emotional expression to enhance motor performance, body awareness, and psychosocial well-being. Emerging evidence suggests that dance-based interventions may contribute to improved pain management, psychological resilience, and emotional health in pediatric oncology populations. However, access to structured physical activity programs remains limited due to treatment-related fatigue, infection risk, travel burden, time constraints, and financial costs.\n\nTelerehabilitation may overcome these barriers by delivering therapy remotely, thereby improving accessibility, reducing logistical constraints, and ensuring continuity of care.\n\nThe aim of this randomized controlled trial is to evaluate the effects of an 8-week telerehabilitation-based dance therapy program (twice weekly, 35-40 minutes per session) on fine and gross motor skills, health-related quality of life, participation in home, school, and community settings, and motivation in children undergoing or recently completing cancer treatment.",[32,658],"Rehabilitation",[32,660,661,662,663,664,665,666],"Dance Therapy","Telerehabilitation","Physiotherapy","Motor Proficiency","Quality of Life","Participation","Motivation",{"date":605,"type":48},{"date":669,"type":22},"2026-05-16",{"date":671,"type":22},"2026-06-30",{"name":673,"class":83},"Akdeniz University",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":680,"eligibilityCriteria":681,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":682,"targetDuration":4,"studyType":23,"phases":684,"briefSummary":685,"conditions":686,"keywords":687,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":563},"100576500","video-inspired-discussions-about-ethical-outcomes-in-pediatrics-100576500","NCT06786104","Video Inspired Discussions About Ethical Outcomes in Pediatrics","A Multisite RWCT Comparing the Effectiveness of a Goals of Care Video and Navigator Intervention, the VIDEO-PEDS Experience, Versus Usual Care in Pediatric Cancer","VIDEO-PEDS","Inclusion Criteria:\n\nPatient\n\n* Age 0-12 years\n* Diagnosed with any type or stage of cancer\n* Receiving cancer directed treatment\n\nParent\n\n* Decision maker for the child.\n* Biological parent, step-parent, legal guardian (e.g., adoptive parent), or grandparent with medical consent authority.\n* Has a child meeting the child inclusion criteria listed above.\n* Able to communicate in English or Spanish (the languages of the video decision aids).\n\nExclusion Criteria:\n\nPatient\n\n* Not receiving primary medical care from the cancer clinic (e.g., second-opinion consultations only)\n* Already referred to and fully consulted by the palliative care team\n* Prognosis of less than a 2-month life expectancy\n\nParent\n\n* Visually impaired beyond 20\u002F200 corrected and unable to view the video (note: hearing impaired is not an exclusion as the videos are closed captioned).\n* Psychological state not appropriate for GOC discussions, as determined by the primary oncologist per the opt-out.\n* Participants who do not speak English or Spanish",{"count":683,"type":22},567,[69],"The goal of this clinical trial is to learn if the VIDEO-PEDS intervention works to improve Goals of Care communication between clinicians and parents of children with cancer.\n\nThe main questions it aims to answer are:\n\nDoes the intervention improve Goals of Care documentation? Does it improve patient outcomes (including less invasive preferences for resuscitation and interventions, less hospital utilization, and more palliative care and hospice use)? Does it improve parent outcomes (including health satisfaction and feeling heard and understood per survey scores)?",[32],[688,689,690],"Advanced Care Planning","Palliative Care","End of Life","2026-05-11",{"date":693,"type":48},"2026-05-14",{"date":695,"type":48},"2026-05-05",{"date":697,"type":22},"2030-04-15",{"name":699,"class":83},"Massachusetts General Hospital"]